Purple Biotech Ltd PPBT
Set alert
1.17 USD +0.09 +8.33%
At close · Oct 30
1.17 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
1.07 Day range 1.17
0.924 52-week range 9.40
- YTD
- -82.22%
- 1 year
- -87.55%
- Open
- 1.09
- Prev close
- 1.08
- Mkt cap
- 1.90M
- Vol
- 41.62K
- Avg vol
- 1.28M
- EPS
- -47.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.07
- High
- 1.17
- Forward P/E
- -1.69
- Beta
- 0.38
- Short ratio
- 0.43
- Inst. own
- 9.33%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.64
- 200-d avg
- 8.21
- 1y target
- 33.00
Financial health
Altman Z-Score
-22.13 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B3 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 4
Valuation
P/E -1.2×
FY 2016 5y median -10.6× FY 2025
P/S 0.0×
FY 2016 5y median 0.0× FY 2025
P/B 3.2×
FY 2016 5y median 5.0× FY 2025
P/FCF -5.7×
FY 2016 5y median -8.6× FY 2025
EV/EBITDA -0.9×
FY 2016 5y median -9.9× FY 2025
EV/Sales 0.0×
FY 2016 5y median 0.0× FY 2025
FCF Yield -17.6%
FY 2016 5y median -11.7% FY 2025
Profitability
Gross Margin 0.0%
FY 2016 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2016 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2016 5y median 0.0% FY 2025
ROE -271.6%
FY 2016 5y median -46.2% FY 2025
ROIC -272.9%
FY 2016 5y median -47.3% FY 2025
ROA -150.2%
FY 2016 5y median -39.7% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2016 FY 2025
Operating Income -149.5%
FY 2016 FY 2025
EPS (diluted) -24.4%
FY 2016 FY 2025
Free Cash Flow 61.4%
FY 2016 FY 2025
Financial Health
Current Ratio 1.3×
FY 2016 5y median 2.2× FY 2025
Quick Ratio 1.3×
FY 2016 5y median 2.2× FY 2025
Debt / Equity 0.0×
FY 2016 5y median 0.0× FY 2025
Net Debt / EBITDA 0.3×
FY 2016 5y median 0.7× FY 2025
Interest Coverage -704×
FY 2016 5y median -337× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31